Individualised incretin-based treatment for type 2 diabetes (Q43004687)

12 November 2017

Individualised incretin-based treatment for type 2 diabetes (English)

1 reference

12 November 2017

1 reference

Michael A Nauck

1

1 reference

PubMed ID

20580425

12 November 2017

Juris J Meier

series ordinal

2

1 reference

PubMed ID

20580425

12 November 2017

language of work or name

English

0 references

publication date

26 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

376

1 reference

12 November 2017

9739

1 reference

12 November 2017

393-394

1 reference

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960998-1

7 January 2021

10.1016/S0140-6736(10)60998-1

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j635chsjmbfufmq7iyp2x5jkpy

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_j635chsjmbfufmq7iyp2x5jkpy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j635chsjmbfufmq7iyp2x5jkpy

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/j635chsjmbfufmq7iyp2x5jkpy

30 July 2022